Amplia targets ovarian cancer in new clinical protein inhibitor trial

🇦🇺 The Sydney Morning Herald (AU) —
Amplia targets ovarian cancer in new clinical protein inhibitor trial

AI Summary

Amplia Therapeutics has initiated a new clinical trial for its protein inhibitor drug narmafotinib, targeting ovarian cancer in collaboration with the Australian research group ANZGOG. This advancement aims to enhance treatment options for patients battling the disease.

Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.

Health Amplia Therapeutics ovarian cancer clinical trial protein inhibitor partnership

Read original source →